Sign In
Buy ZLDPF
$49.02
+0 (+0%)
At Close: Jun 03, 2026
Zealand Pharma A/S (ZLDPF) Q3 2025 Earnings Call Transcript
07:51pm, Thursday, 13'th Nov 2025
Zealand Pharma A/S (OTCPK:ZLDPF) Q3 2025 Earnings Call November 13, 2025 8:00 AM EST Company Participants Adam Steensberg - President & CEO David Kendall - Executive VP, Chief Medical Officer & Head o
Zealand Pharma scraps obesity drug candidate, citing crowded market, Bloomberg News reports
05:23am, Thursday, 13'th Nov 2025
Zealand Pharma is halting development of a potential next-generation obesity drug after concluding the market has become too crowded for it to stand out, Bloomberg News reported on Thursday, citing an
Zealand Pharma A/S (ZLDPF) Presents at Bank of America Global Healthcare Conference 2025 Transcript
10:27am, Thursday, 25'th Sep 2025
Zealand Pharma A/S (OTCPK:ZLDPF) Bank of America Global Healthcare Conference 2025 September 25, 2025 5:45 AM EDT Company Participants David Kendall - Executive VP, Chief Medical Officer & Head of R&D
Zealand Pharma may sell future obesity drug direct to patients, amid market shifts
09:42am, Monday, 22'nd Sep 2025
Zealand Pharma is considering a direct-to-patient sales model for its experimental weight-loss drug alongside traditional insurer channels, its CEO told Reuters in an interview on Monday, citing shift
Zealand Pharma A/S (ZLDPF) Presents at Cantor Global Healthcare Conference 2025 Transcript
01:22am, Friday, 05'th Sep 2025
Zealand Pharma A/S (OTCPK:ZLDPF) Cantor Global Healthcare Conference 2025 September 4, 2025 8:00 AM EDT Company Participants Adam Steensberg - President & CEO Conference Call Participants Prakhar Agra
Zealand Pharma A/S (ZLDPF) Q2 2025 Earnings Call Transcript
01:30pm, Thursday, 14'th Aug 2025
Zealand Pharma A/S (OTCPK:ZLDPF) Q2 2025 Earnings Call August 14, 2025 8:00 AM ET Company Participants Adam Langer - Corporate Participant Adam Sinding Steensberg - President & CEO David M. Kendall -
Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz
06:10pm, Monday, 23'rd Jun 2025
Jared Holxz, Mizuho, joins 'Fast Money' to talk competition in the obesity drug space.
Zealand Pharma Obesity Therapy Shows Positive Trial Results
01:10pm, Wednesday, 18'th Jun 2025
Zealand Pharma said its obesity treatment dapiglutide showed positive topline results in its latest trial, demonstrating its further potential for weight loss and to treat obesity-related comorbiditie
Zealand Pharma A/S (ZLDPF) Q1 2025 Earnings Call Transcript
02:07pm, Friday, 09'th May 2025
Zealand Pharma A/S (OTCPK:ZLDPF) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Adam Lange - Vice President, Investor Relations Adam Steensberg - President & Chief Execut
Inside the deal: Roche and Zealand Pharma's $5.3 billion obesity drug gambit
01:19am, Friday, 02'nd May 2025
Roche and Zealand Pharma in March struck a deal worth up to $5.3 billion to co-develop and co-commercialize amylin analog petrelintide as a potentially "next generation" weight loss drug. Executives a
Zealand Pharma AS (ZLDPF) Stock Jumps 8.0%: Will It Continue to Soar?
05:25am, Thursday, 01'st May 2025
Zealand Pharma AS (ZLDPF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength d
Zealand Pharma begins mid-stage trial for obesity drug candidate in people with type 2 diabetes
01:58am, Thursday, 24'th Apr 2025
Danish biotechnology company Zealand Pharma said on Thursday it had enrolled the first patient in a mid-stage trial with its weight-loss drug candidate petrelintide in people with overweight or obesit
Zealand Pharma Goes on Hiring Spree as It Gears Up for Obesity Tie-Up With Roche
10:27am, Friday, 11'th Apr 2025
The Danish biotech's recruitment drive began last summer when data from an early-stage trial of the drug—petrelintide—showed its potential.
Zealand Pharma's new drug petrelintide will help people lose weight: CEO
12:30pm, Wednesday, 12'th Mar 2025
Zealand Pharma CEO Adam Steensberg discusses the company's new collaboration and licensing agreement with Roche as well as the commercial opportunities for its amylin analog molecule.
Roche and Zealand Pharma strike $5.3 billion deal for new obesity drug candidate
06:55am, Wednesday, 12'th Mar 2025
Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Danish biotech Zealand Pharma's obesity drug candidate. Shares of Zealand Pharma jumped as
